(E)-4-Bromostyryl-4-nitrobenzylsulfone | 334969-04-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-4-Bromostyryl-4-nitrobenzylsulfone
• 英文别名: 1-[[(E)-2-(4-bromophenyl)ethenyl]sulfonylmethyl]-4-nitrobenzene
• CAS: 334969-04-9
• 化学式: C₁₅H₁₂BrNO₄S
• 分子量: 382.235
• InChiKey: HCZDTCCNOSRKQO-MDZDMXLPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  88.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-4-Bromostyryl-4-nitrobenzylsulfone 在 tin(ll) chloride 作用下， 以 乙醇 、 异丙醇 为溶剂， 反应 2.0h， 生成 {4-[(E)-2-(4-Bromo-phenyl)-ethenesulfonylmethyl]-phenyl}-(6,7-dimethoxy-quinazolin-4-yl)-amine
  参考文献：
  名称：

  Synthesis and biological evaluation of [4-(2-phenylethenesulfonylmethyl)phenyl]-quinazolin-4-yl-amines as orally active anti-cancer agents

  摘要：

  A new series of [4-(2-phenylethenesulfonylmethyl)phenyl]quinazolin-4-yl-amines was prepared and tested for its in vitro cytotoxic activity against a panel of 12 human cancer cell lines. Compounds 9, 15, 24 and 31 showed good in vitro activity and were further tested for their in vivo efficacy in the HT-29 human colon adeno carcinoma xenograft model. Compound 9 exhibited promising activity in this model. Dose-response studies for this compound against HT-29 human colon adeno carcinoma xenografts at 100, 200 and 400 mg/kg doses were performed. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.10.020
• 作为产物：
  描述：

  [(4-硝基苄基)硫代]乙酸 在 Oxone 、 溶剂黄146 、 苄胺 作用下， 以 二氯甲烷 、 水 、 叔丁醇 为溶剂， 反应 12.0h， 生成 (E)-4-Bromostyryl-4-nitrobenzylsulfone
  参考文献：
  名称：

  Synthesis and biological evaluation of [4-(2-phenylethenesulfonylmethyl)phenyl]-quinazolin-4-yl-amines as orally active anti-cancer agents

  摘要：

  A new series of [4-(2-phenylethenesulfonylmethyl)phenyl]quinazolin-4-yl-amines was prepared and tested for its in vitro cytotoxic activity against a panel of 12 human cancer cell lines. Compounds 9, 15, 24 and 31 showed good in vitro activity and were further tested for their in vivo efficacy in the HT-29 human colon adeno carcinoma xenograft model. Compound 9 exhibited promising activity in this model. Dose-response studies for this compound against HT-29 human colon adeno carcinoma xenografts at 100, 200 and 400 mg/kg doses were performed. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.10.020

文献信息

• (E)-4-carboxystyrl-4-chlorobenzyl sulfone and pharmaceutical compositions thereof
  申请人：——

  公开号：US20030149109A1

  公开（公告）日：2003-08-07

  Pre-treatment with &agr;,&bgr; unsaturated aryl sulfones protects normal cells from the cytotoxic side effects of two classes of anticancer chemotherapeutics. Administration of a cytoprotective sulfone compound to a patient prior to anticancer chemotherapy with a mitotic phase cell cycle inhibitor or topoisomerase inhibitor reduces or eliminates the cytotoxic side effects of the anticancer agent on normal cells. The cytoprotective effect of the &agr;,&bgr; unsaturated aryl sulfone allows the clinician to safely increasing the dosage of the anticancer chemotherapeutic.

  使用α,β-不饱和芳基磺酮进行预处理可以保护正常细胞免受两类抗癌化疗药物的细胞毒副作用。在患者进行含细胞周期有丝分裂期抑制剂或拓扑异构酶抑制剂的抗癌化疗之前，给予一种细胞保护性磺酮化合物，可以减少或消除抗癌药物对正常细胞的细胞毒副作用。α,β-不饱和芳基磺酮的细胞保护作用使得临床医生可以安全地增加抗癌化疗药物的剂量。
• Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
  申请人：——

  公开号：US20040214903A1

  公开（公告）日：2004-10-28

  Pre-treatment with &agr;,&bgr; unsaturated aryl sulfones protects normal cells from the cytotoxic side effects of two classes of anticancer chemotherapeutics. Administration of a cytoprotective sulfone compound to a patient prior to anticancer chemotherapy with a mitotic phase cell cycle inhibitor or topoisomerase inhibitor reduces or eliminates the cytotoxic side effects of the anticancer agent on normal cells. The cytoprotective effect of the &agr;,&bgr; unsaturated aryl sulfone allows the clinician to safely increasing the dosage of the anticancer chemotherapeutic.

  预处理使用α，β不饱和芳基磺酮可以保护正常细胞免受两类抗癌化疗药物的细胞毒副作用。在使用有丝分裂期细胞周期抑制剂或拓扑异构酶抑制剂的抗癌化疗前向患者给予细胞保护性磺酮化合物，可以减少或消除抗癌药物对正常细胞的细胞毒副作用。α，β不饱和芳基磺酮的细胞保护作用使临床医生可以安全地增加抗癌化疗药物的剂量。
• Formulations of radioprotective alpha, beta unsaturated aryl sulfones
  申请人：Onconova Therapeutics, Inc.

  公开号：EP2769719A1

  公开（公告）日：2014-08-27

  Solution and suspension formulations are provided for administration prior to or after exposure to ionizing radiation for reducing toxic effects of the radiation in a subject which comprises an effective amount of at least one radioprotective α, β unsaturated aryl sulfone wherein the composition has a pH within the range of about 8 to about 9.

  本发明提供了溶液和悬浮液制剂，用于在电离辐射照射前或照射后给药，以减少辐射对受试者的毒性影响，该制剂包含有效量的至少一种辐射保护性 α、β 不饱和芳基砜，其中组合物的 pH 值在约 8 到约 9 的范围内。
• METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS
  申请人：Temple University of the CommonwealthSystem of Higher Education

  公开号：EP1223923A1

  公开（公告）日：2002-07-24
• EP1223923A4
  申请人：——

  公开号：EP1223923A4

  公开（公告）日：2007-09-05